This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertaux, C. Articles by Dragic, T. Search for Related Content PubMed PubMed Citation Articles by Bertaux, C. Articles by Dragic, T.

 Previous Article  |  Next Article 

Journal of Virology, May 2006, p. 4940-4948, Vol. 80, No. 10
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.10.4940-4948.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry

Albert Einstein College of Medicine, Department of Microbiology and Immunology, 1300 Morris Park Avenue, Bronx, New York 10461

Received 26 December 2005/ Accepted 22 February 2006

The CD81 tetraspanin was first identified as a hepatitis C virus (HCV) receptor by its ability to bind the soluble ectodomain of envelope glycoprotein E2 (sE2). More recently, it has been suggested that CD81 is necessary but not sufficient for HCV entry into target cells. Here we present further evidence that putative human hepatocyte-specific factors act in concert with CD81 to mediate sE2 binding and HCV pseudoparticle (HCVpp) entry. Moreover, we show that CD81-mediated HCVpp entry entails E2 binding to residues in the large extracellular loop as well as molecular events mediated by the transmembrane and intracellular domains of CD81. The concept that CD81 receptor function progresses in stages is further supported by our finding that anti-CD81 monoclonal antibodies inhibit HCVpp entry by different mechanisms. The half-life of CD81-HCVpp binding was determined to be approximately 17 min, and we propose that binding is followed by CD81 oligomerization, partitioning into cholesterol-rich membrane domains, or other, lateral protein-protein interactions. This results in the formation of a receptor-virus complex that undergoes endocytosis and pH-dependent membrane fusion.

This article has been cited by other articles:

• Meertens, L., Bertaux, C., Cukierman, L., Cormier, E., Lavillette, D., Cosset, F.-L., Dragic, T. (2008). The Tight Junction Proteins Claudin-1, -6, and -9 Are Entry Cofactors for Hepatitis C Virus. J. Virol. 82: 3555-3560 [Abstract] [Full Text]  
• Tellinghuisen, T. L., Evans, M. J., von Hahn, T., You, S., Rice, C. M. (2007). Studying Hepatitis C Virus: Making the Best of a Bad Virus. J. Virol. 81: 8853-8867 [Full Text]  
• Chang, Y., Finnemann, S. C. (2007). Tetraspanin CD81 is required for the {alpha}vbeta5-integrin-dependent particle-binding step of RPE phagocytosis. J. Cell Sci. 120: 3053-3063 [Abstract] [Full Text]  
• Falkowska, E., Kajumo, F., Garcia, E., Reinus, J., Dragic, T. (2007). Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization. J. Virol. 81: 8072-8079 [Abstract] [Full Text]  
• Meertens, L., Bertaux, C., Dragic, T. (2006). Hepatitis C Virus Entry Requires a Critical Postinternalization Step and Delivery to Early Endosomes via Clathrin-Coated Vesicles. J. Virol. 80: 11571-11578 [Abstract] [Full Text]  
• Flint, M., von Hahn, T., Zhang, J., Farquhar, M., Jones, C. T., Balfe, P., Rice, C. M., McKeating, J. A. (2006). Diverse CD81 Proteins Support Hepatitis C Virus Infection. J. Virol. 80: 11331-11342 [Abstract] [Full Text]